| 產(chǎn)品編號 | bsm-61252R |
| 英文名稱 | CTNNA1 Recombinant Rabbit mAb |
| 中文名稱 | α-連環(huán)蛋白重組兔單抗 |
| 別 名 | 102 kDa cadherin-associated protein; alpha E-catenin; CATNA1; CTN1; Cadherin-associated protein; catenin alpha-1; Catenin alpha 1; CTNNA1. |
| 抗體來源 | Rabbit |
| 克隆類型 | Recombinant |
| 克 隆 號 | 12F9 |
| 交叉反應(yīng) | Human,Mouse,Rat |
| 產(chǎn)品應(yīng)用 | WB=1:500-1:5000,IHC-P=1:100-1:200,IHC-F=1:100-1:200,IF=1:50-1:200,Flow-Cyt=1:20-1:100,ICC/IF=1:50-1:200,IP=1:20-1:50
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 理論分子量 | 100 kDa |
| 檢測分子量 | 100 |
| 性 狀 | Liquid |
| 免 疫 原 | A synthesized peptide derived from human alpha Catenin: 1-65/906 |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 緩 沖 液 | 10mM phosphate buffered saline(pH 7.4) with 150mM sodium chloride, 0.05% BSA, 0.02% Proclin300 and 50% glycerol. |
| 保存條件 | Store at 4℃ for short term. Store at -20℃ for long term. Avoid repeated freeze/thaw cycles. |
| 注意事項(xiàng) | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| PubMed | PubMed |
| 產(chǎn)品介紹 |
Adherens junctions are dynamic structures that form cell-cell contacts and are important in development, differentiation, tissue integrity, morphology and cell polarity. They are composed of the transmembrane proteins, cadherins, which bind cadherins on adjacent cells in a calcium-dependent manner. SWISS: P35221 Gene ID: 1495 細(xì)胞粘附蛋白（Call Adhesion Protein） α-catenin是一種多功能的蛋白質(zhì)，能鏈接E-\N-\P-鈣粘附分子,具有參與細(xì)胞粘附和介導(dǎo)信號轉(zhuǎn)導(dǎo)的雙重功能，并與腫瘤的發(fā)生發(fā)展及浸潤密切相關(guān)。 在正常個體中，βα-catenin和鈣黏蛋白形成復(fù)合體，介導(dǎo)同型細(xì)胞的粘附，維持細(xì)胞的穩(wěn)定；同時(shí)，α-catenin作為Wnt/α-catenin信號通路的關(guān)鍵成員在介導(dǎo)信號轉(zhuǎn)導(dǎo)過程中調(diào)控細(xì)胞的增殖和凋亡。 在惡性腫瘤中，α連環(huán)蛋白的表達(dá)呈現(xiàn)明顯的異質(zhì)性，促使細(xì)胞異常增殖，還可使細(xì)胞之間的黏附性減 |
| 產(chǎn)品圖片 |
25 ug total protein per lane of various lysates (see on figure) probed with CTNNA1 monoclonal antibody, unconjugated (bsm-61252R) at 1:1000 dilution and 4°C overnight incubation. Followed by conjugated secondary antibody incubation at r.t. for 60 min.
|
